摘要
T cell-redirecting bispecific antibodies are specifically designed to bind to tumor-associated antigens,thereby engaging with CD3 on the T cell receptor.This linkage between tumor cells and T cells actively triggers T cell activation and initiates targeted killing of the identified tumor cells.These antibodies have emerged as one of the most promising avenues within tumor immunotherapy.However,despite success in treating hematological malignancies,significant advancements in solid tumors have yet to be explored.In this review,we aim to address the critical challenges associated with T cellredirecting bispecific antibodies and explore novel strategies to overcome these obstacles,with the ultimate goal of expanding the application of this therapy to include solid tumors.
基金
supported by the National Natural Science Foundation of China(Nos.32070940 and 81991491)
the China Postdoctoral Science Foundation(No.2021M700115)
the Postdoctoral Innovation Talents Support Program(No.BX20220189,China)
the Science and Technology Planning Project of Fujian Province(No.2022L3080,China)
the CAMS Innovation Fund for Medical Sciences(No.2019RU022,China).
